Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-17
2006-10-17
Jiang, Shaojia A. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07122528
ABSTRACT:
The present invention relates to the use of 5-substituted nucleosides and/or the prodrugs thereof together with at least one active substance in order to produce a drug or combination preparation for resistance-free therapy of infectious diseases caused by bacteria or protozoa.
REFERENCES:
patent: 3287351 (1966-11-01), Cantineau et al.
patent: 4656260 (1987-04-01), Kato et al.
patent: 4894365 (1990-01-01), De Clercq et al.
patent: 4902678 (1990-02-01), Smith
patent: 4988678 (1991-01-01), De Clercq et al.
patent: 5064946 (1991-11-01), Shaver et al.
patent: 5250296 (1993-10-01), Ootsu
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5831064 (1998-11-01), Chang et al.
patent: 6011000 (2000-01-01), Perrine et al.
patent: 6245750 (2001-06-01), Shepard
patent: 6589941 (2003-07-01), Fahrig et al.
patent: 19705277 (1997-11-01), None
patent: 0143987 (1985-06-01), None
patent: 0488718 (1992-06-01), None
patent: 1473148 (1977-05-01), None
patent: 2310139 (1997-08-01), None
Banker, G.S. et al, Modern Pharmaceutics, 1996, p. 596.
David Romero et al., “Gene Amplification and Genomic Plasticity in Praokaryotes”, Annu. Rev. Genet., vol. 31, pp. 91-111 (1997).
Alan F. Cowman et al., “Antifolate Drug Selection Results in Duplication and Rearrangement of Chromosome 7 . inPlasmodium chabaudi”, Molecular and Cellular Biology, vol. 9, No. 11, pp. 5182-5188 (1989).
Alan F. Cowman et al., “Chromosomal Rearrangements and Point Mutations in the DHFR-TS Gene ofPlasmodium chabaudiUnder Antifolate Selection”, Molecular and Biochemical Parasitology, vol. 42, pp. 21-29 (1990).
Manami Tanaka et al., “Mutant dihydrofolate Reductase-thymidylate Synthase Genes in Pyrimethamine-ResistantPlasmodium falciparumwith Polymorphic Chromosome Duplications”, Molecular and Biochemical Parasitology, vol. 42, pp. 83-91 (1990).
Manami Tanaka et al., “Dihydrofolate Reductase Mutations and Chromosomal Changes Associated with Pyrimethamine Resistance ofPlasmodium falciparum”, Molecular and Biochemical Parasitology, vol. 39, pp. 127-134 (1990).
Junichi Watanabe et al., “Establishing a Physical Map of Chromosome No. 4 ofPlasmodium falciparum”, Molecular and Biochemical Parasitology, vol. 65, pp. 189-200 (1994).
Simon J. Foote et al., “Amplification of Multidrug Resistance Gene in Some Chloroquine-Resistant Isolates of P. falciparum”, Cell, vol. 57, pp. 921-930 (1989).
Craig M. Wilson et al., “Amplification of a Gene Related to Mammalian mdr Genes in Drug-ResistantPlasmodium falciparum”, Science, vol. 244, pp. 1184-1186 (1989).
Alan F. Cowman et al., “Selection for Mefloquine Resistance inPlasmodium falciparumis Linked to Amplification of thepfmdr1Gene and Cross-Resistance to Halofantyrine and Quinine”, Proc. Natl. Acad. Sci. USA, vol. 97, pp. 1143-1147 (1994).
M. Ouellette et al., “Drug Resistance and P-glycoprotein Gene Amplification in the Protozoan ParasiteLeishmania”, Res. Microbiol., vol. 142, pp. 737-746 (1991).
Katherine Grondin et al., “Linear Amplicons as Precursors of Amplified Circles in Methotrexate-ResistantLeishmania tarentolae”, Nucleic Acids Research, vol. 26, No. 14, pp. 3372-3378 (1998).
Flora E. Arana et al., “Involvement of Thiol Metabolism in Resistance to Glucantime inLeishmania tropica”, Biochemical Pharmacology, vol. 56, pp. 1201-1208 (1998).
Anass Haimeur et al., “Gene Amplification inLeishmania tarentoaeSelected for Resistance to Sodium Stibogluconate”, Antimicrobial Agents and Chemotherapy, vol. 42, No. 7, pp. 1689-1694 (1998).
Christoph Kündig et al., “role of the Locus and of the Resistance Gene on Gene Amplification Frequency in Methotrexate ResistantLeishmania tarentolae” Nucleic Acids Research, vol. 27, No. 18, pp. 3653-3659 (1999).
S.N. Pancheva, “Methotrexate Potentiates Anti-Herpes Simplex Virus Type I Activity of E-5(2-Bromovinyl)-2′-Deoxyuridine”, Acta Virologica, vol. 39, pp. 117-119 (1995).
Chakrabartty et al., “Loss of Plasmid Linked Drug Resistance After Treatment with Iod-deoxyuridine”, Indian Journal of Experimental Biology, vol. 22, pp. 333-334 (1984).
S. Locarnini, “Hepatitis B Antiviral Therapy”, Today's Life Science, vol. 2, No. 9pp. 32, 34, 36-38 and 80 (1990).
Wildiers, “Oral (E)-5-(2-Bromovinyl)-2′-Deoxyuridine Treatment of Severe Herpres Zoster in Cancer Patients”, European Journal of Cancer & Clinical Oncology, vol. 20, pp. 471-476 (1984).
Chi et al., “Iododeoxyuridine Chemosensitization of cis-Diamminedichloroplatinum(II) in Human Bladder Cancer Cells”, Cancer Research, vol. 54, pp. 2701-2706 (1994).
Wroblewski et al., “The Possible role of Altered Nucleotide Metabolism in Cisplatin Resistance”, J. Cell Pharmacol., vol. 1, pp. 2-7 (1990).
Hirohashi et al., “Genetic Alterations in Human Gastric Cancer”, Cancer Cells, vol. 3, pp. 49-52 (1991).
Sasano et al., Protooncogene Amplification and Tumor Ploidy in Human Ovarian Neoplasms, Human Pathology, vol. 21, pp. 382-391 (1990).
Borg et al., “c-myc Amplification is an Independent Prognostic Factor in Postmenopausal Breast Cancer”, Int. J. Cancer, vol. 51, pp. 687-691 (1992).
Borg et al., “Association of INT2/HST1 Coamplification in Primary Breast Cancer with Hormone-Dependent Phenotype and Poor Prognosis”, Br. J. Cancer, vol. 63, pp. 136-142 (1991).
Descotes et al., “Human Breast Cancer: Correlation Study Between HER-2
eu Amplification and Prognostic Factors in an Unselected Population”, Anticancer Research, vol. 13, pp. 119-124 (1993).
Klijn et al., “The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients”, Endocrine Reviews, vol. 13, pp. 3-17 (1992).
Tsuda et al., “High Incidence of Coamplification of hst-1 and int-2 Genese in Human Esophageal Carcinomas”, Cancer Research, vol. 49, pp. 55505-55508 (1989).
Kennedy, “Prevention of Carcinogenesis by Protease Inhibitors”, Cancer Research (Suppl.), vol. 54, pp. 1999s-2005s (1994).
Troll et al., “Trumorigenesis in Mouse Skin: Inhibition by Synthetic-Inhibitors of Proteases”, Science, vol. 169, pp. 1211-1213 (1970).
Moscow et al., “Multidrug Resistance”, Journal of the National Cancer Institute, vol. 80, pp. 14-20 (1988).
Oshiro et al., “Genotoxic Properties of (E)-5-(2-Bromovinyl)-2′-deoxyuridine (BVDU)”, Fundamental and Applied Toxicology, vol. 18, pp. 491-498 (1992).
Iigo et al. Jpn. J. Cancer Res., vol. 81, pp. 431-435 (1990).
Sharon B. Bordow, et al., “Expression of the Multidrug Resistance-Associated Protein (MRP) Gene Correlates with Amplification and Overexpression of N-myc Oncogene in Childhood Neuroblastoma”, Cancer Research, 54, pp. 5036-5040 (Oct. 1994).
Alok Bhushan, et al., “Expression of c-fos in Human and Murine Multidrug-Resistant Cells”, Molecular Pharmacology, 42, pp. 69-74 (1992).
Alok Bhushan, et al., “Expression of c-fos Precedes MDR3 in Vincristine and Adriamycin Selected Multidrug Resistant Murine Erythroleukemia Cells”, Biochemical and Biophysical Research Communications, 226, pp. 819-821 (1996).
Thomas Braun, et al., “Differential Expression of Myogenic Determination Genes in Muscle Cells: Possible Autoactivation by the Myf Gene Products”, EMBO Journal, vol. 8, No. 12, pp. 3617-3625 (1989).
Rudolf Fahrig, “Anti-Recombinogenic and Convertible Co-Mutagenic Effects of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and Other 5-substituted Pyrimidine Nucleoside Analogs inS. cerevisiaeMP1”, Mutation Research, 372, pp. 133-139 (1996).
Rudolf Fahrig, et al., “Induction or Suppression of SV40 Amplification by Genotoxic Carcinogens, Non-Genotoxic Carcinogens or Tumor Promoters”, Mutation Research, 356, pp. 217-224 (1996).
Roy A. Frye, et al., “Detection of Amplified On
Fahrig Rudolf Hinrich Hermann
Sonntag Denise
Greenblum & Bernstein P.L.C.
Jiang Shaojia A.
Krishnan Ganapathy
RESPROTECT GmbH
LandOfFree
Use of 5-substituted nucleosides and/or prodrugs thereof in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 5-substituted nucleosides and/or prodrugs thereof in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 5-substituted nucleosides and/or prodrugs thereof in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3616121